Acadia Pharmaceuticals Inc. (ACAD)
Last updated: 2026-10-24 20:52:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Acadia Pharmaceuticals Inc. (ACAD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $19.72, with a market capitalization of $3.50B and a P/E ratio of 9.20. Over the past 52 weeks, its price has ranged from $18.39 to $30.96. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$3.50B | |
$20.22 | |
$58.72 | |
$0.65 | |
$20.31 | |
634.15K | |
1.87M | |
9.20 | |
$30.96 | |
$18.39 | |
-- | |
-- |
Acadia Pharmaceuticals Inc. (ACAD) Latest Closing Stock Price
Acadia Pharmaceuticals Inc. (ACAD) last closed at $20.31 as of 2026-10-23 23:31:00, unchanged from the previous close of $20.31.
During the latest regular trading session, ACAD traded between $0.65 and $58.72, with a volume of 634.15K shares. The closing price was near the middle and near the lower end of its 52-week range.
Acadia Pharmaceuticals Inc. (ACAD) 7-Day Stock Price Change
Over the past seven days, Acadia Pharmaceuticals Inc. (ACAD) moved from $19.71 to $19.72, representing a gain of 0.05% ($0.01).
The stock traded between $18.87 and $20.57 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.45 million shares, down versus the previous seven-day period, indicating lower trading activity.
ACAD 52-Week Price Position
Position in Range: 10.6%
ACAD is currently trading at $19.72, placing it 10.6% of the way from its 52-week low of $18.39 to its 52-week high of $30.96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Acadia Pharmaceuticals Inc. (ACAD)?
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Acadia Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 798 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Acadia Pharmaceuticals Inc. (ACAD) Stock on MEXC
Eligible investors can buy real shares of Acadia Pharmaceuticals Inc. (ACAD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Acadia Pharmaceuticals Inc. (ACAD) stock price today?
2.Is ACAD stock going up or down today?
3.What is ACAD pre-market price?
4.What is ACAD after-hours price?
5.Is ACAD stock trading now?
6.Where does ACAD sit relative to its 52-week high and low?
7.What sector is Acadia Pharmaceuticals Inc. in?
8.What is Acadia Pharmaceuticals Inc.'s market capitalization and where is it listed?
9.How is ACAD valued in terms of P/E ratio and EPS?
10.Does Acadia Pharmaceuticals Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ACAD Stock Calculator
Estimate the value between ACAD shares and USD.
ACAD Shares to USD
1.00 ACAD shares = 19.72 USD
Calculations are estimates based on the latest available price and are for reference only.


